Innovative Therapeutics in Oncology and Neuroscience

Adagrasib Potentially Differentiated Therapy in NSCLC for Patients with KRAS G12C Mutations Approved (U.S.) 2L+ NSCLC: KRYSTAL-1 Study1 KRAZATI KRAZATI (adagrasib tablets) MIRATI 200 mg 180 tablets NOC 80739-812-18 Ra Only KRAZATI (adagrasib tablets) MIRATI THERAPEUTICE 200 mg 180 tablets ORR (n=128): 43.0% mPFS (n=128): 6.9 months (95% CI, 5.4-8.7) mOS (n=132): 14.1 months (95% CI, 9.2-18.7) Exploratory analyses suggested durable clinical benefit in patients with treated, stable CNS metastases at baseline (mOS of 14.7 months) CNS metastases occur in 27%-42% of patients with KRASG12C-mutated NSCLC at diagnosis • • Current Status & Next steps FDA accelerated approval in 2L+ NSCLC with KRASG12C mutation in December 2022 Topline data readout for the ongoing confirmatory KRYSTAL-12 Phase 3 study expected in 1H 2024 Zai Lab is preparing for China NDA submission in 2024 33 1L NSCLC with TPS ≥ 50% • Demonstrated early efficacy in combination with pembrolizumab • • 63% ORR 2,3,4 (n=56) • Substantially exceeds standard of care historical benchmark of 39%-45% 5,6 Combination is well tolerated with low rates of clinically meaningful liver TRAES Abbreviation: Central nervous system (CNS). Sources: WCLC 2023; BMS presentation on the acquisition of Mirati on October 8, 2023. Next step Enrollment in Phase 3 adagrasib +/- pembrolizumab study . 1L NSCLC with TPS < 50% Strategy to raise the standard of care through combination with chemotherapy and pembrolizumab Adagrasib chemo-pembro combination Phase 2 study underway (KRYSTAL-17) Next step Data for KRYSTAL-17 Phase 2 study expected in 1H 2024 Notes: The trademarks and registered trademarks within are the property of their respective owners. (1) Two-year follow-up of data for 132 patients in Phase 1/1b dose escalation and expansion cohorts and Phase 2 Cohort A of KRYSTAL-1 (Data as of 1 January 2023; median follow-up: 26.9 months); (2) One confirmed response confirmed subsequent to data cut off; full analysis set includes 3 protocol violations (n=56); (3) Excluding 3 protocol violations, ORR was 66% (n=53); (4) Among clinical activity evaluable (CAE) patients, defined as receiving at least one dose of adagrasib (400 mg BID) + pembrolizumab, having measurable disease at baseline, and having at least one post-baseline tumor assessment, the ÒRR was 71% (n=49); (5) ORR of 39% from KEYNOTE-42 and ORR of 45% from KEYNOTE-24; (6) For illustrative purposes only: no head-to-head clinical trial has been conducted. Clinical Data - Oncology

View entire presentation